Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Zachary Klinger

Interventional Pain Medicine Corbin, KY Doctor of Osteopathy

NPI 1831620319 CMS profile 5137453

1498 W Cumberland Gap Pkwy, Corbin, KY 40701

Open in the dashboard

General payments

$10,143

100 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zachary Klinger of Corbin, KY is reported in the CMS Open Payments database as having received $10,143 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115 4
2024 General $2,745 39
2023 General $1,371 18
2022 General $3,627 18
2021 General $2,285 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zachary Klinger
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Zachary Klinger were reported at $115. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Zachary Klinger Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $2,285 $552 $167–$1,554 $132
2022 $3,627 $605 $187–$1,924 $149
2023 $1,371 $671 $195–$1,915 $160
2024 $2,745 $684 $206–$1,837 $164
2025 $115 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $4,125 32 payments
  2. Medtronic, Inc. $3,633 33 payments
  3. Nevro Corp. $1,217 15 payments
  4. Boston Scientific Corporation $566 10 payments
  5. Relievant Medsystems, Inc. $388 2 payments
  6. Stryker Corporation $61 2 payments
  7. Painteq LLC $58 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $24 1 payment
  9. Vertos Medical, Inc. $22 1 payment
  10. AbbVie, Inc. $20 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $6,078 27 payments
  2. Food and Beverage $4,065 73 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $2,440 8 payments
  2. SYNCHROMEDII $2,336 22 payments
  3. RESTORE $1,103 6 payments
  4. Intracept Pain $898 9 payments
  5. Proclaim IPG $833 10 payments
  6. PROCLAIM Neuromodulation $557 8 payments
  7. Omnia $540 5 payments
  8. Intracept Pain $388 2 payments
  9. Intracept Pain $388 2 payments
  10. Intracept Pain $388 2 payments
  11. Other $1,440 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,683

Median for Anesthesiology: 322

Drug cost

$35,078

Median for Anesthesiology: $8,738

Branded share of claims

72.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 793 $14,878
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 421 $12,042
Pregabalin Generic 65 $3,403
Gabapentin Generic 219 $2,070
Oxycodone Hcl Generic 72 $1,419
Meloxicam Generic 12 $391
Tramadol Hcl Generic 69 $376
Morphine Sulfate Er Morphine Sulfate Brand 12 $285
Tizanidine Hcl Generic 20 $214

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$134,864

Of which drugs: $2,610

Medicare patients

368

Average age 73

Services billed

2,653

238 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Diabetes 29%
Ischemic heart disease 24%
Chronic kidney disease 22%
Osteoporosis 22%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 80 380 $1,950
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 428 $291
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 51 722 $66

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $24
$24 — —
UBRELVY
  • AbbVie, Inc. $10
$10 — —
BOTOX
  • AbbVie, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record